Cargando…

Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer death worldwide, for which better knowledge in molecular prognostic factors is needed to improve clinical outcome. This study aimed to investigate the clinical significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 in NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sunpaweravong, Patrapim, Thongwatchara, Patcharaporn, Chotipanvithayakul, Rassamee, Sangkhathat, Surasak, Thongsuksai, Paramee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036383/ https://www.ncbi.nlm.nih.gov/pubmed/35479767 http://dx.doi.org/10.1177/11795549221092747

Ejemplares similares

Copy number gains of chromosome 17 identified by dual in situ hybridization in non-small cell lung cancer tissue correlate with overexpression of c-Myc
por: Sunpaweravong, Patrapim, et al.
Publicado: (2022)

Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand
por: Dechaphunkul, Arunee, et al.
Publicado: (2022)

Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance
por: Leeha, Marisa, et al.
Publicado: (2023)

Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil in locally advanced nasopharyngeal carcinoma
por: Dechaphunkul, Tanadech, et al.
Publicado: (2011)

Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand
por: Wonglhow, Jirapat, et al.
Publicado: (2023)

Methylation of 14-3-3σ gene and prognostic significance of 14-3-3σ expression in non-small cell lung cancer
por: Raungrut, Pritsana, et al.
Publicado: (2017)

Effects of Character Strength-Based Intervention vs Group Counseling on Post-Traumatic Growth, Well-Being, and Depression Among University Students During the COVID-19 Pandemic in Guangdong, China: A Non-Inferiority Trial
por: Yu, Yulan, et al.
Publicado: (2022)

Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis
por: Sunpaweravong, Somkiat, et al.
Publicado: (2019)

Metastatic Primary Testicular Neuroendocrine Carcinoma Associated with Somatic Malignant Transformation of Teratoma: A Rare Case Report
por: Wonglhow, Jirapat, et al.
Publicado: (2022)

Modification of the association between experience of economic distress during the COVID-19 pandemic and behavioral health outcomes by availability of emergency cash reserves: findings from a nationally-representative survey in Thailand
por: Wichaidit, Wit, et al.
Publicado: (2022)

Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
por: Cao, Yabing, et al.
Publicado: (2019)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

MicroRNA Isolation by Trizol-Based Method and Its Stability in Stored Serum and cDNA Derivatives
por: Trakunram, Keson, et al.
Publicado: (2019)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
por: Lee, Jongmin, et al.
Publicado: (2018)

Programmatic Cost-Effectiveness of a Second-Time Visit to Detect New Tuberculosis and Diabetes Mellitus in TB Contact Tracing in Myanmar
por: Zayar, Nyi Nyi, et al.
Publicado: (2022)

Sensory stimulation program improves developments of preterm infants in Southwest China: A randomized controlled trial
por: Zheng, Wenjing, et al.
Publicado: (2022)

Diagnostic and prognostic value of serum miR-145 and vascular endothelial growth factor in non-small cell lung cancer
por: Geater, Sarayut Lucien, et al.
Publicado: (2022)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

Serum miRNAs associated with tumor-promoting cytokines in non-small cell lung cancer
por: Chaniad, Pichitpon, et al.
Publicado: (2020)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
por: Pilling, Amanda B., et al.
Publicado: (2018)

Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
por: Ekin, Zübeyde, et al.
Publicado: (2021)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Role of innate lymphoid cells in obesity and metabolic disease
por: Saetang, Jirakrit, et al.
Publicado: (2018)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors
por: Leonetti, Alessandro, et al.
Publicado: (2020)

Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1(G2032R) and ALK(G1202R)
por: Liu, Siming, et al.
Publicado: (2023)

Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
por: Liu, Jun, et al.
Publicado: (2018)

Impact of EFEMP1 on the survival outcome of biliary atresia in Thai infants
por: Laochareonsuk, Wison, et al.
Publicado: (2022)

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology
por: Patil, Tejas, et al.
Publicado: (2022)

Computational discovery of binding mode of anti-TRBC1 antibody and predicted key amino acids of TRBC1
por: Saetang, Jirakrit, et al.
Publicado: (2022)

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
por: Tunthanathip, Thara, et al.
Publicado: (2021)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jpal0kqd87iro5koc4cr4n84mm